Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin versus Livergol for non-alcoholic fatty liver disease
IRCT20210514051287N1Phase 3Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Metformin with Livergol (2 arms). Primary endpoints: Body mass index, Total cholesterol and 8 more. Started Apr 2022; status: completed.
02
Drugs
metforminsilybum marianum extract
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20210514051287N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210514051287N1.